



Medicinal Plants as Promising Alternatives for Treating Helminthiasis: A review

Douti Fekandine Victoire^{1*}, Djeri Bouraima¹ and Karou Damitoti Simplicé¹

¹École Supérieure des Techniques Biologiques et Alimentaires (ESTBA), Université de Lomé, Lomé, Togo.

Abstract

Introduction: Helminth infections pose a significant threat to public health and affect both humans and animals. These infections affect nearly one-fifth of the global population and result in substantial livestock losses. These infections are treated with anthelmintic drugs, but the parasites' resistance to these common drugs suggests the need for new anthelmintic agents. This review elucidates the effectiveness of vegetable compounds against helminth infections with a mode of action similar to that of conventional anthelmintics.

Methods: Although several hundred articles were identified, this review found over one hundred and thirty articles relevant to our keywords after sorting them. These articles were selected from databases such as Google Scholar, PubMed, ScienceDirect, and BMC, using search terms such as “helminths,” “anthelmintic plants,” and “alternative medicine.” The selected studies focused on helminthiasis and the anthelmintic activity of plants. WHO data were also used to obtain information on the prevalence and epidemiology of helminthiasis.

Results: Most conventional anthelmintics, commonly used to treat helminths, belong to the benzimidazole (albendazole, mebendazole), macrocyclic lactone (ivermectin), and pyrazinoisoquinolines (praziquantel) families. However, their frequent use has led to resistance, as reported in numerous studies.

Nevertheless, plants can be an alternative, as many plants are used in traditional medicine to treat helminth infections. The anthelmintic effects of these plants are often attributed to their secondary metabolites, including tannins, polyphenols, flavonoids, alkaloids, saponins, steroids, terpenoids, essential oils, and fatty acids. These compounds act by inhibiting larval development, egg hatching, and worm motility by damaging worm cuticles, which leads to parasite paralysis and death. However, researchers must focus on clinical tests after isolating the bioactive compound of these plants in the view to setup new anthelmintic drugs to face resistances observed.

Conclusion: Many medicinal plants contain anthelmintic molecules that can be used as alternative treatments for helminths. Thus, researchers must investigate more on clinical tests of the isolated bioactive compounds for setting up new anthelmintic drugs.

Keywords: Helminth infections, anthelmintic drugs, resistance, plants, alternative medicine.

Introduction

Helminthiasis refers to infections caused by parasitic worms, called helminths, in their larval or adult stages. These parasites are classified into three main groups on the basis of their morphology: nematodes (roundworms), cestodes (segmented flatworms), and trematodes (non-segmented flatworms) (1). Nematodes include intestinal worms and filarial worms, which cause lymphatic filariasis and

onchocerciasis, respectively. Cestodes are flatworms that cause taeniasis, while trematodes are flukes that cause fluke disease (1). These multicellular organisms feed on the host's nutrients once inside the body, causing diseases in organs such as the gastrointestinal tract, tissues, and lymphatic system (2).

Helminth infections are a significant public health concern for both humans and animals. They infect nearly one-fifth of the world's population and cause substantial losses of

Edited by

Simfele Hombamane Christelle,
University of Lome, Lome, Togo

Reviewed by

HOEKOU Yao, University of Lome,
Lome, Togo

GBEKLEY Efui Holaly, University of
Lome, Lome, Togo

*Corresponding author

Douti V. Fekandine
victoirefekandined@gmail.com

Received: 04 August 2025

Accepted: 02 January 2026

Published: 09 March 2026

Citation

Douti FV, Djeri B, Karou DS.
Medicinal Plants as Promising
Alternatives for Treating
Helminthiasis: A review.
WoSciMIB. 2026; 01(06):1-16. DOI:
[10.5281/zenodo.18909103](https://doi.org/10.5281/zenodo.18909103)

livestock (3). Most helminth infections are classified as neglected tropical diseases (NTDs) (4) due to the lack of funding for drug discovery (5, 6). More than two billion people are estimated to be affected worldwide (7, 8), particularly in tropical and subtropical regions where sanitary conditions are poor (9). The highest prevalence is found in sub-Saharan Africa, Asia, and South America (10, 11). An estimated 500 million people in sub-Saharan Africa are affected (12) with notable concentrations of cases of soil-transmitted helminthiasis (STH), schistosomiasis, lymphatic filariasis, and other diseases (10). These endemic areas are characterized by inadequate sanitation and limited access to clean drinking water (2).

Togo has made significant efforts to combat these diseases. In 2017, it became the first sub-Saharan African country to eliminate lymphatic filariasis as a public health problem (13). However, despite these advances, STH remains endemic in six rural villages in central Togo, affecting 74.38% of the population (14). This persistence is due to conditions that favor transmission, such as limited access to safe drinking water and adequate sanitation facilities. Symptoms of helminthiasis depend on several factors, including the species of helminth, the severity of the infection, and the age of the host. Common symptoms include anemia, eosinophilia, liver and spleen inflammation, malnutrition, intestinal obstruction, weight loss, and pneumonia (15).

Treatment of helminthiasis mainly involves administering anthelmintic drugs (16). While these drugs are effective, their extensive use has resulted in resistance among certain parasite species (17). Additionally, these treatments can cause undesirable side effects, including gastrointestinal disorders, allergic reactions, and, in rare cases, neurotoxic effects (18). Furthermore, access to these drugs is limited in many rural areas of sub-Saharan Africa because of cost, distribution logistics, and lack of awareness among affected populations. Unmet therapeutic needs lead to high mortality and disability rates, creating a significant social and economic burden (19). These challenges underscore the urgent need for more accessible, effective, and sustainable therapeutic alternatives (20). Drug innovation outcomes for a particular disease reflect investment in research and development (R&D). However, it is known that drug discovery and development (DDD) is costly and inherently risky. Therefore, funding limitations and the insufficient economic returns of NTD drugs restrict innovation efforts in this area (21).

For centuries, medicinal plants have been used in traditional medicine to treat various conditions, including parasitic infections. These plants are rich sources of bioactive compounds with potential anthelmintic properties. Recent studies have demonstrated the effectiveness of certain plant extracts against particular helminths, indicating their

potential as alternatives to synthetic drugs (7). The use of medicinal plants has several advantages. They are generally more accessible and affordable for local populations, highly culturally acceptable, and offer a variety of mechanisms of action, thereby reducing the risk of resistance development (20). Additionally, scientific exploration of these plants can lead to the discovery of new therapeutic compounds and promote traditional knowledge (22).

The purpose of this review is to identify and analyze medicinal plants with demonstrated anthelmintic activity, particularly those used in sub-Saharan Africa. This review examines the available scientific evidence regarding plant efficacy, mechanisms of action, safety, and potential integration into strategies to control helminthiasis. The goal is to encourage the use of medicinal plants as alternative treatments for helminths and to create a comprehensive database of plants used to treat helminthiasis to guide future research on anthelmintic agents.

Methods

Several hundred articles were identified in total, but after careful screening, 137 were selected. Our selection criteria were articles whose studies focused on helminthiasis and the anthelmintic activity of plants. After evaluating the methods used and the results obtained, we only included the most relevant articles. We found publications by searching online article databases, such as: Google Scholar, PubMed, ScienceDirect and BMC. The World Health Organization website was used to identify the prevalence and epidemiology of helminthiasis (Figure 1). All of the consulted articles were written in English. The search terms "helminths" and "anthelmintic plants" were used in conjunction with "alternative medicine" to identify relevant articles.

Results and discussion

Epidemiology and significance of helminth infections

Since the beginning of human history, helminths have infested humans and they still do today. Some studies reveal that infections caused by human intestinal parasites date back to prehistoric times (23, 24). Studies estimate that hundreds of millions of people worldwide are infected with helminths (25). These parasitic worm infections evolve over time in humans (26). Helminth infections pose a serious threat to public health in developing countries (27). The epidemiology of helminth infections is influenced by several factors, including population growth, standard of living, global warming (28), age, and geographical variations (29, 30). Hookworm infection affects nearly 40 to 50 million school-age children and 7 million pregnant women, for whom it is a leading cause of anemia.




Figure 1: Representation of literature review steps. A total of 444 articles were identified and selected on Google Scholar, PubMed, ScienceDirect, BMC and World Health Organization. After eligibility test, 172 were used for this based on their relevance to the topic. Finally, 137 were include in this review

Lymphatic filariasis affects 46 to 51 million people, and onchocerciasis affects nearly 37 million people (12). Hyperreactive onchocerciasis is characterized by an excessive immune response involving an increase in pro-inflammatory Th17 and Th2 cells. This response is accompanied by a reduction in regulatory T cells, which typically moderate immune responses (31). Helminthiasis prevalence in the adult population increased despite the implementation of the Mass Drug Administration (MDA) in school-aged children (32). The morbidity associated with helminthiasis considerably affects children's cognitive development and physical growth (8, 9, 27) ; representing a significant medical and economic burden .

Consequently, morbidity and mortality rates associated with helminths are increasing worldwide (8). Some of these

infections are classified as neglected tropical diseases (NTDs) (10), as they primarily affect impoverished communities (33). The World Health Organization (WHO) has identified seventeen NTDs (34). However, the WHO's MDA programs, which aim to reduce or eliminate these diseases, currently target seven of them: lymphatic filariasis, onchocerciasis, schistosomiasis, blinding trachoma, and geohelminthiasis (ascariasis, trichuriasis, and hookworm) (35). Taeniasis/cysticercosis is one of the seventeen NTDs (36). It is an infection that affects humans and animals, including cattle and pigs, and is caused by *Taenia saginata* or *Taenia solium*. These two species are prevalent in several regions of the world, including Africa. Cases have been reported in the Middle East and North Africa (37), Taeniasis/cysticercosis is one of the seventeen NTDs (36).

It is an infection that affects humans and animals, including cattle and pigs, and is caused by *Taenia saginata* or *Taenia solium*. These two species are prevalent in several regions of the world, including Africa. Cases have been reported in the Middle East and North Africa (37), East and South Africa (38, 39) and Central and West Africa, where they cause significant economic losses (40). A dose of praziquantel 10 mg/kg, niclosamide 2 g, or albendazole 400 mg in triple doses could be used in MDA programs to combat *Taenia solium* cysticercosis (41). However, a recent study investigated the effectiveness of a single dose of niclosamide, which is only 75% effective (42). Therefore, there is an urgent need to develop new therapeutic solutions, as existing treatments for helminth infections are limited.

Mechanism of action and limitations of some commonly used anthelmintics

There are only a few drugs currently available to treat these infections. Albendazole, oxamniquine, praziquantel, and ivermectin are the most common ones used to treat human helminthiasis (27). These anthelmintics primarily target structures or functions essential to the survival of helminths.

Albendazole, a benzimidazole derivative, binds to the parasite's β -tubulins, thereby inhibiting their polymerization into microtubules (43). This disruption interferes with several processes vital to parasite survival, including intracellular transport, glucose uptake, cell division, and cytoskeletal structure, ultimately leading to its immobilization and death (44).

On the other hand, ivermectin acts on glutamate-dependent chloride channels (GluCl_s), which are present in the muscle and nerve cells of nematodes (43). GluCl_s are found in invertebrates, but not in humans (7). Binding to these channels induces hyperpolarization through the influx of chloride ions, which leads to the death of the worm (5). Additionally, GluCl_s exhibit high affinity for ivermectin, correlating with this drug's anthelmintic potency (28). Ivermectin acts as an antagonist of gamma-aminobutyric acid (GABA) and nicotinic receptors on parasite muscle cells (45). This results in the inhibition of movement and feeding, which leads to nematode death. However, ivermectin is microfilaricidal and does not effectively kill adult worms; it only blocks the release of microfilariae for a few months after treatment (15).

Oxamniquine, which is primarily used to treat *Schistosoma mansoni* infections (46), is a prodrug activated by the parasite-specific enzyme sulfotransferase (SmSULT) (47). The resulting reactive metabolite covalently binds to DNA, causing irreversible alterations in cellular functions, particularly in male *Schistosoma mansoni* worms (48).

On the other hand, praziquantel acts by increasing the parasite's membrane permeability to calcium (Ca^{2+}). This causes muscle contraction, leading to intense muscle paralysis and disintegration of the integument. Thus, the parasite is exposed to the host's immune responses, particularly inflammatory reactions (49, 50). Praziquantel is much more active than oxamniquine because it is effective against all species of adult schistosomes. However, it remains ineffective against their immature forms for reasons that are still unknown (51). Praziquantel is also effective against other species of trematodes and acts against the larval, immature, and mature stages of cestodes. It is particularly effective in treating taeniasis and cysticercosis (52).

Unfortunately, the use of the same drugs for such a long time has led to the emergence of resistance. Several studies have reported the reduced efficacy of currently available human anthelmintics, and the scope of resistance is likely to increase (53). Additionally, resistance to an anthelmintic in a given class tends to be accompanied by resistance to other anthelmintics in the same class, a phenomenon known as secondary resistance. This occurs because anthelmintics in the same class act similarly (43). Thus, new innovative therapies with different modes of action for sustainable anthelmintic control are needed (54).

Knowing the mechanism of action of anthelmintics helps us understand their resistance process and how to address it.

Problems related to anthelmintic resistance

The previously described mechanisms of action are fundamental to the effectiveness of antiparasitic treatments and the prevention of resistance. However, cases of resistance to anthelmintics in certain parasites have been reported in recent years (55) and pose a significant threat to human and animal health (28). In vivo methods, such as the stool egg count reduction test, and in vitro methods, such as egg hatching tests, larval motility tests, larval development tests, and PCR, can detect anthelmintic resistance (17).

This is exemplified by a study conducted by Jacob et al. who reported that the emergence of albendazole resistance is associated with the E198K mutation in the parasite's β -tubulin gene (44). This mutation replaces glutamic acid (E) at position 198 with lysine (K), thereby altering albendazole's binding affinity. Glutamic acid is negatively charged, while lysine is positively charged. This change disrupts essential electrostatic interactions, reducing albendazole's ability to properly bind to the β -tubulin protein (5).

Ivermectin resistance was also indicated. UNC-9 is a gap junction protein that facilitates electrical communication between neurons and plays a pivotal role in neuronal signaling and locomotion in *Caenorhabditis elegans*. In

UNC-9 mutants, impaired electrical coupling between motor neurons alters how signals propagate, which can make ivermectin less effective. This is because the coordinated hyperactivation that normally causes paralysis is blunted. Thus, the mutation limits ivermectin's ability to induce neuromuscular failure and provides the UNC-9 mutant worms with a survival advantage (5).

Chevalier et al. (2019) demonstrated that resistance to oxamniquine is due to recessive, loss-of-function mutations in the sulfotransferase (SmSULT-OR) of the parasitic organism *Schistosoma mansoni*, as well as several other mutations (p.W120R, p.N171IfsX28), including a confirmed deletion (p.E142del). These mutations are widespread in natural parasite populations under minimal drug pressure and predate the deployment of oxamniquine (56).

Reduced sensitivity to praziquantel has also been detected in parasites from patients who have failed treatment with praziquantel. Da Silva et al. reported resistance to praziquantel in Senegal. The administration of a 40 mg/kg dose of praziquantel during a schistosomiasis epidemic resulted in cure rates of only 18%-39% (50).

In response to cases of resistance to pharmaceutical drugs, studies are being conducted to develop new, sustainable, effective, innovative, and safe therapeutic solutions based on natural plant products (57).

Potential of medicinal plants as an alternative

Medicinal plants play an important role in managing parasitic diseases in humans and livestock, particularly in Africa (58). Humans have used them to treat ailments since several centuries, and they are still used daily around the world to treat various illnesses (59). Their accessibility and low cost mean that the global population is increasingly turning to them (60). Currently, approximately 80% of the global population uses plants directly or indirectly to treat diseases (61). Approximately 20,000 plant species are estimated to be used in traditional medicine worldwide, demonstrating the potential of natural products and the possibility of developing new essential antiparasitic drugs from these plants (62). However, of the 71 new drugs approved between 1981 and 2019, only 7 were derived entirely from natural products. Unfortunately, there are currently no anthelmintic drugs approved for use that have been developed from plant sources (58).

In Africa, most of the population relies on traditional, plant-based medicine for their primary health needs (63, 64). Certain plants have been identified as treatments for helminthiasis in regions where it is prevalent (65). For example, in southern Africa, the use of *Zanthoxylum capense* (Thumb.) Harv., *Acacia karroo* Hayne, and *Abrus precatorius* (L.) to treat helminth infections, schistosomiasis, leishmaniasis, and trypanosomiasis has been reported by

Cock et al. (66). In Central Africa, specifically in Gabon, a survey listed 24 plants used to treat intestinal, cutaneous, and ocular helminthiasis. The most commonly cited plants are *Cylicodiscus gabonensis* Harms, *Zanthoxylum gillettii* (De Wild.), *Plagiostyles Africana* (Müll.Arg.), *Duguetia barteri* (Benth.) Chatrou, and *Annickia chlorantha* (Oliv.) Setten & Maas (67). Another study in northern Cameroon listed 22 anthelmintic plants used in traditional medicine. *Tephrosia pedicellata* Baker, *Aristolochia baetica* (L.), and *Abelmoschus esculentus* (Okra) were the most effective (100%) against the gastrointestinal nematode *Haemonchus contortus* (68). In East Africa, particularly in Kenya, medicinal plants are the primary treatment for helminthiasis in human and veterinary medicine (69).

Several medicinal plants in sub-Saharan Africa are known for their ability to treat parasitic diseases, including leishmaniasis, trypanosomiasis, helminthic infections, onchocerciasis, lymphatic filariasis, schistosomiasis, toxoplasmosis, and echinococcosis (70). However, more research is needed to evaluate the efficacy and safety of these plants in order to develop accessible, affordable, and safe herbal therapies (71).

In vitro anthelmintic activities

An *in vitro* study demonstrated that three plants known for their anthelmintic properties — *Aframomum melegueta* K. Schum., *Xylopiya aethiopicum* (Dunal) A. Rich., and *Khaya senegalensis* A. Juss. — possessed anti-inflammatory and anti-Th17-Th2 activity in subjects with hyperreactive onchocerciasis (72). A study made by Waterman et al. revealed strong *in vitro* anthelmintic activity in eight of the seventeen plant species tested on the levamisole-resistant strain of *Caenorhabditis elegans*. These include *Acacia polyacantha* Willd., *Anogeissus leiocarpus* (DC.) Guill. & Perr., *Bridelia micrantha* (Hochst.) Baill., *Cassia sieberiana* DC., *Combretum nigricans* Lepr. ex Guill. & Perr., *Grewia bicolor* Juss., *Strychnos spinosa* Lam., and *Ziziphus mucronata* Willd. (73). Another study examining 29 medicinal plants used in Ghana revealed that *Clausena anisata* Willd., *Zanthoxylum zanthoxyloides* Lam., and *Punica granatum* (L.), exhibited stronger *in vitro* anthelmintic activity against *Ascaris suum* (74). A survey conducted by Ataba et al. in Togo reported that *Aframomum melegueta* K. Schum., *Khaya senegalensis* A. Juss., and *Xylopiya aethiopicum* (Dunal) A. Rich., were the three most widely used of the 41 cited plants and possessed anthelmintic properties against *Litomosoides sigmodontis microfilariae* (75). Thus, Douti et al. demonstrated the *in vitro* anthelmintic activity of hydroethanolic extracts and fractions (dichloromethane, ether, and aqueous) of *Aframomum melegueta* and *Xylopiya aethiopicum*, on adult worms and *Tænia* spp cells (76).

In vivo anthelmintic activities

In vivo studies are the most useful method for validating the anthelmintic potential of plants (77). However, most studies that screen for anthelmintic activity in plant extracts are performed *in vitro* rather than *in vivo* (78). Ali et al. reported that *in vitro* studies were almost five times greater than *in vivo* studies, and they also highlighted inconsistent toxicology assessments across studies (79). In practice, many anthelmintic studies either omit or limit rigorous toxicity testing to a single cytotoxicity assay, so host toxicity issues remain under-evaluated (80). For example, *Xylopia aethiopica* (Dunal) A. Rich., known for its anthelmintic properties, was found to be not cytotoxic in cytotoxicity testing, but toxicological impact assessment revealed inflammation and vascular congestion of the liver and kidneys (81, 82).

Hu *et al.* also reported a lack of studies on the optimization of the clinical efficacy of potential anthelmintic treatments (83). Thus, numerous plant extracts showing *in vitro* or *in vivo* efficacy have not progressed to the clinical validation of new anthelmintics. According to Nixon et al., most promising preclinical hits rarely become clinically validated drugs due to barriers in bringing anthelmintics to human clinical trials (84). A review compiling plant-derived leads repeatedly emphasizes that, although many extracts show *in vitro* or *in vivo* efficacy, clinical evaluation in humans is lacking (58).

However, all of these tests are necessary to confirm the efficacy and safety of plant-based drugs for pharmacological validation before new anthelmintics can be developed.

Main plant metabolites with anthelmintic activity

Authors In recent decades, researchers have focused on developing medicines from plant extracts because their success rate is higher than that of chemical synthesis (85). Plants are a source of several broad-spectrum secondary metabolites that contribute to their defense mechanisms (28) and can serve as a natural solution for parasite resistance. These metabolites can be classified into several categories. For example, alkaloids are known for their analgesic properties, phenolic compounds can act as antioxidants, flavonoids have anti-inflammatory properties, and saponins can act as diuretics. Tannins act as natural antibiotics (59). Plants also contain fatty acids that paralyze or even kill parasitic worms (86); and essential oils that prevent egg hatching and larval and adult development (87). A study by Mondal et al. showed that the anthelmintic activity of the ethanolic extract of *Alternanthera sessilis* (L.), against *Haemonchus contortus* is due to phytochemical compounds,

including flavonoids, saponins, steroids, tannins, terpenoids, and reducing sugars (88). Additionally, polyphenolic compounds, particularly coumarin and caffeic acid, have been reported to have anthelmintic activity against *Cooperia punctata*, a nematode found in cattle (89). Polyphenols are widely used in traditional medicine to treat nematode infections (90). A study by Jato et al. revealed that polyphenols and terpenoids are the most frequently cited anthelmintic compounds (58). The anthelmintic activity of condensed tannins has also been documented. They bind to cuticle proteins, causing the cuticle to break down. They also inhibit energy production by the worm, leading to its death by energy depletion (91). A study by Ndjonka et al. on medicinal plants and their natural compounds revealed that tannins, alkaloids, triterpenoids, and essential oils were active against *Onchocerca* spp (92). Maestrini et al. demonstrated that saponins from *Medicago polymorpha* (L.), cultivars exhibited significant anthelmintic activity by inhibiting the hatching of gastrointestinal strongyle nematode eggs in sheep (93).

The anthelmintic activities of these secondary metabolites are due to their bioactive compounds. Consequently, research is increasingly focused on identifying and isolating these molecules because this is the first step in developing new anthelmintic drugs.

Bioactive compounds isolated from plants with anthelmintic activity

In general, the medicinal properties of plants are due to the bioactive compounds they contain (7). Certain active compounds isolated from plants have demonstrated anthelmintic activity against different helminth species. For example, luteolin, a compound derived from *Ajania nubigena* (Wallich ex Candolle), has demonstrated broad-spectrum activity against *Schistosoma mansoni* and *Trichuris muris*. It has also been shown to be effective against schistosome larvae, which are naturally resistant to praziquantel, the standard treatment (94). Additionally, quercetin, a naturally occurring plant flavonoid, caused lesions in the *Haemonchus contortus* parasite, demonstrating the anthelmintic activity of this compound against all stages of worm development (95).

As a mode of action, the bioactive molecules and phytochemical compounds in medicinal plants can act individually or synergistically against parasites (59). Some act as acetylcholinesterase inhibitors, which leads to an accumulation of acetylcholine and causes flaccid paralysis in worms. *Momordica charantia* (L.), for example, is a plant rich in phytochemical compounds, including the alkaloid charantin and the saponins karavilagenin, karaviloside, kuguacine, momordicine, momordicoside, and momordinate, all of which have antiparasitic properties (96). Other anthelmintics cause paralysis in worms by inducing oxidative

stress and altering the activity of stress response enzymes, such as catalase, superoxide dismutase, and glutathione Peroxidase. This occurs with certain flavonoids, including quercetin (95).

Fahs and colleagues demonstrated that a group of avocado fatty alcohols/acetates (AFAs) exhibited anthelmintic activity by interfering with the lipid metabolism of the nematodes used in the study (3). This mode of action involves impaired respiration due to mitochondrial damage, which causes paralysis of the worms. Biochemical and genetic tests revealed that AFAs inhibit POD-2, the gene that encodes acetyl-CoA carboxylase, an enzyme that limits lipid biosynthesis (3).

These studies demonstrate that, in many cases, these compounds impact helminth survival and can therefore be exploited by the pharmaceutical industry or medicine.

Table 1 lists anthelmintic plants with identified bioactive compounds, their metabolite categories, target helminths, and mechanisms of action.

Methodologies used to assess the anthelmintic activity of plants

Although there are many challenges associated with the use of natural products, such as extraction difficulties and the evaluation of compounds present in extracts, as well as the challenge of distinguishing between general cytotoxicity and true antiparasitic activity, the development of new technologies is enabling the discovery and development of new drugs (62). The anthelmintic efficacy of plants can be assessed using various *in vitro* or *in vivo* methods. Jato et al. reported that, in their investigation of the anthelmintic activity of medicinal plants, more than 64% of studies used *in vitro* tests on parasitic and non-parasitic nematode models, evaluating parameters such as the inhibition of egg hatching and larval migration, as well as the paralyzing effect of these plant extracts (58).

In vitro anthelmintic tests

To determine drug efficacy, numerous *in vitro* methods have been developed for parasitic worms that enable cellular monitoring. These methods include tools based on video image analysis (97), microscopy, metabolic enzymes, fluorescence and impedance (98).

Microscopy

Light microscopy can be used to determine the number of parasites present before and after the administration of an

anthelmintic. Electron microscopy can also be used to observe the effects of a plant extract on the membrane of a nematode. For example, in a study by Williams et al., the direct anthelmintic effects of condensed tannins against *Ascaris* were clearly observed by light microscopy. This was achieved by reducing the migratory capacity of stage three (L3) larvae, which then resulted in increased motility and survival of stage four (L4) larvae recovered from pigs. Using transmission electron microscopy, Williams et al. also reported that condensed tannins caused significant damage to the cuticle and digestive tissues of *Ascaris suum* larvae (91).

Viability tests

The trypan blue exclusion test is a method for determining the number of viable cells present in a cell suspension (99). This technique is based on the principle that the intact cell membranes of living cells exclude the dye, while the cell membranes of dead cells allow the dye to penetrate. The test is performed by mixing a cell suspension with trypan blue, and then observing the cells under a microscope to determine whether they absorb the dye (blue cytoplasm) or not (clear cytoplasm) (100). Thus, in addition to human cells, the trypan blue viability test can be performed on different types of animal cells, such as mammalian cells and worm cells. This is the case of the trypan blue viability tests carried out on schistosome larvae after culture in 96-well culture plates with the test compounds at various concentrations. Observation under a light microscope enabled the live and dead schistosomules in each well to be counted manually and the 50% inhibitory concentration (IC₅₀) values to be determined (94). Propidium Iodide (PI) is also a cell viability assay based on the principle that intact cell membranes exclude dye from living cells, whereas damaged cell membranes allow the dye to pass into dead cells (99). PI is unique in that it is a fluorescent dye that binds to DNA inside dead cells. Consequently, dead cells are mainly detected and quantified by flow cytometry (101) or fluorescence microscopy, unlike trypan blue, which is observed via light microscopy (102).

Test for larval motility and migration inhibition

This test evaluates the efficacy of a treatment, such as a plant extract or molecule, in causing paralysis and death in larvae. Observations can be macroscopic (visual scoring) or microscopic. A combination of motility and migration inhibition tests is often employed to evaluate the *in vitro* anthelmintic properties of various compounds against larvae. Williams et al. demonstrated that ten ethanolic plant extracts inhibited the migration of at least 50% of *Ascaris suum* larvae (74).

Table 1: Plant-derived anthelmintic compounds and their mode of action on worms

Source plants	Active compounds	Categories of metabolites	Target helminths	<i>In vitro</i> or <i>in vivo</i> activity	References
<i>Acacia cochliacantha</i> (Humb. & Bonpl. ex Willd.)	Caffeic acid, methyl caffeate, methyl p-coumarate, quercetin	Caffeoyl and coumaroyl derivatives	<i>Haemonchus contortus</i>	Inhibition of egg hatching	(103)
<i>Aframomum megueta</i> (K. Schum.)	6 paradol, gingerol, shogaol	Polyphenols, flavonoids, tannins, alkaloids, essential oils	<i>Litomosoides sigmodontis</i>	Microfilaricide activity	(104-106)
<i>Ajania nubigena</i> (Wallich ex Candolle)	Luteolin	Flavonoids	<i>Schistosoma mansoni</i> , <i>Trichuris muris</i>	Damage the cuticle, bands, and bacillary glands	(107)
<i>Albizia ferruginea</i> (Guill. & Perr.)	Oleanane-type	Saponins, tannins, glycosides, alkaloids, coumarins	<i>Pheretima posthuma</i> , <i>Haemonchus contortus</i>	Paralysis and death of worms	(108)
<i>Alectryon oleifolius</i> (Desf.)	Procyanidin A2	Tannins	<i>Equine cyathostomes</i>	Inhibition of larval development and migration	(109)
<i>Allium sativum</i> (L.)	Allicin, curcumin	Organosulfur compound, polyphenol	<i>Schistosoma mansoni</i>	Reduction in the number of worms and egg load	(110)
<i>Alternanthera sessilis</i> (L.)	Ellagic acid	Tannins	<i>Haemonchus contortus</i>	Inhibition of egg hatching and adult worm motility	(88)
<i>Avena sativa</i> (L.)	Avenacoside B, 26-desglucoavenacoside B	Saponins	<i>Heligmosomoides bakeri</i>	Morphological changes in larvae, inhibition of glycoprotein pump activity	(111)
<i>Camellia sinensis</i> (L.) Kuntze	Epigallocatechin-(2 β →O→7',4 β →8')-epicatechin-3'-O-gallate	Polyphenols (Tannin gallate)	<i>Caenorhabditis elegans</i>	Toxic activity on oviparous adult worms	(112)
<i>Carica papaya</i> (L.)	Albendazole oxide, 2-Hydroxy-1-(hydroxymethyl)ethyl ester,	Alkaloids, glycosides, flavonoids, saponins, phenols, terpenoids, fatty acid ester	<i>Allolobophora caliginosa</i>	Worms' structural changes (reduced size and increased cuticle thickness)	(113)
<i>Chenopodium ambrosioides</i> (L.)	Ascaridole	Essential oil	<i>Schistosoma mansoni</i>	Similar anti-schistosomal properties like Praziquantel	(114)

Source plants	Active compounds	Categories of metabolites	Target helminths	<i>In vitro</i> or <i>in vivo</i> activity	References
<i>Combretum mucronatum</i> (Schu. & Thonn.)	Catechin, epicatechin	Flavonoids and proanthocyanidins	<i>Ascaris suum</i> , <i>Trichuris suis</i> , <i>caninum</i>	Inhibition of larval migration	(115)
<i>Corallocarpus epigaeus</i> (Rottler) Hook.f.)	n-Hexadecanoic acid, octadecanoic acid	Lipid (fatty acid)	<i>Pheretima posthuma</i>	Paralysis and death of worms	(86)
<i>Cucurbita pepo</i> (L.)	Cucurbitine, berberine, palmatine	Amino acids, alkaloids, fatty acids, nucleosides	<i>Caenorhabditis elegans</i> <i>Heligmosoides bakeri</i>	Eggs hatching and worm's motility inhibition	(116)
<i>Curtisia dentata</i> (Thunb.) C.A.Sm.	Betulinic acid, lupeol, ursolic acid	Terpénoïdes	<i>Caenorhabditis elegans</i> <i>Haemonchus contortus</i>	Inhibition of larval motility	(117)
<i>Cymbopogon citratus</i> (DC.) Stapf	Citral	Alkaloids, tannins, steroids, saponins, terpenoids, flavonoids	<i>Haemonchus placei</i>	Kill worms	(118)
<i>Indigofera tinctoria</i> (L.)	Degueline	Isoflavonoids	<i>Haemonchus contortus</i>	Modulation of oxidative phosphorylation	(119)
<i>Juniperus procera</i> (Hochst. ex Endl.)	Totarol	Terpenoid	<i>Caenorhabditis elegans</i>	Nematicidal activity	(120)
<i>Melaleuca alternifolia</i> (Maiden & Betche) Cheel	Terpinen-4-ol	Essential oils	<i>Haemonchus contortus</i>	Ovicidal and larvicidal activity	(121)
<i>Momordica charantia</i> (L.)	Momordicins, momordins, momordicosides, caravilagins, caravilosides, kuguacins	Saponins	<i>Ascaris spp</i> <i>Fasciola hepatica</i> <i>Strongyloides spp</i> <i>Caenorhabditis elegans</i>	Worms paralysis and death, Inhibition of embryonic development of eggs, Tegument rupture	(122)
<i>Persea americana</i> Mill.	Quercetin, epicatechin	Total phenols, condensed tannins, flavonoids	<i>Haemonchus contortus</i>	Larvicidal activity	(123)

Source plants	Active compounds	Categories of metabolites	Target helminths	<i>In vitro</i> or <i>in vivo</i> activity	References
<i>Piper sylvaticum</i> Roxb.	Piperine	Alkaloids, flavonoids, tannins, and saponins	<i>Tubifex tubifex</i>	Paralytic effect on worms comparable to levamisole	(124)
<i>Punica granatum</i> (L.)	5-hydroxymethylfurfural, D-sucrose, sorbitol	Sugars, alcohols	<i>Strongyloides papillosus</i>	Larvicidal activity	(125)
<i>Sesbania sesban</i> (L.)	Octadecanoic acid, 2-hydroxy-1-(hydroxymethyl) ethyl ester	Fatty acids	<i>Raillietina echinobothrida</i> , <i>Syphacia obvelata</i>	Damage mouth, suckers, and cuticle/tegument of worms	(126)
<i>Tagetes filifolia</i> (Lagasca)	Chlorogenic acid	Phenolic	<i>Haemonchus contortus</i>	Egg hatching inhibition and larvae mortality	(127)
<i>Tetradenia riparia</i> (Hochst.) Codd	8(14),15-Sandaracopimaradiene-7 α ,18-diol	Diterpene	<i>Caenorhabditis elegans</i>	Kill worms	(128)
<i>Thymus vulgaris</i> (L.)	Thymol	Essential oils	<i>Haemonchus contortus</i>	Inhibition of egg hatching, larval and adult development	(129)
<i>Tribulus terrestris</i> (L.)	Tribulosin, β -sitostérol-D-glucoside	Steroids, saponins, alkaloids, flavonoids, vitamins, tannins, fatty acids	<i>Ascaridia galli</i>	Anti-ascarid activity	(130, 131)
<i>Vernonia amygdalina</i> (Delile)	Vernoniamyoside A–D, vernoamyoside D et vernonioside	Tannins, saponin glycosides, reducing sugars, alkaloids, steroids, flavonoids, terpenoids	<i>Pheretima posthuma</i>	Paralysis and death of worms	(132, 133)
<i>Xylopi aethiopica</i> (Dunal) A. Rich.	Xylopic acid (diterpene)	Tannins, saponins, glycosides, flavonoids and alkaloids	<i>Pheretima posthuma</i>	Kill worms	(134, 135)

Real-time motility test

xCELLigence a biosensor technology, is an impedance-based technique for real-time analysis of living cells (126). It enables the continuous monitoring of cell health, behavior, and function. This technology uses custom-made E-plates with gold electrodes to measure electrical changes related to the presence and activity of cells, including growth, migration, proliferation, propagation, cell type, and viability (131). It is a motility-viability test applicable to a variety of helminths (126).

Thus, Wangchuk et al. used the xCELLigence Real-Time Motility Assay for Worms (xWORM) to demonstrate the dual anthelmintic activities of two compounds, luteolin and (3R,6R)-linalool oxide acetate, derived from *Ajania nubigena* (Wallich ex Candolle), against *Trichuris muris* and *Schistosoma mansoni* (94). The xWORM study uses a real-time analysis system, enabling parameters to be optimized and sensitivity to be improved through standardized statistical analysis. This makes the system a valuable platform for measuring drug responses in a multitude of experimental settings (131).

In vivo anthelmintic tests

There are different murine models depending on the species of helminth used for infestation. First, the mice are infested with the appropriate species of helminth. Then, a certain number of days are allowed to pass to allow the infection to manifest. Finally, the models are treated with the plant extracts or compounds of interest. The mice were sacrificed to evaluate the efficacy of the treatment in reducing the number of larvae in the infected groups treated with plant extracts compared to the groups infected and treated with the reference drug (positive control) or infected but not treated (negative control) [132]. Ojo et al. demonstrated that *Gongronema latifolium* (Benth.) and *Picralima nitida* (Stapf.) T. Durand & H. Durand exhibited anthelmintic activity in vivo when extracts of these plants were administered to mice, as compared to untreated mice. The 500 mg/kg dose of *Picralima nitida* extract caused 92.45% chemosuppression in worms, which is comparable to the 92.61% achieved with albendazole [133].

Development of anthelmintic vaccines based on immunogenic plant compounds

Due to helminths' resistance to conventional drugs, developing helminth vaccine antigens based on immunogenic plant compounds is a promising area of research. Nevertheless, one study reported that vaccines

against ascariasis and trichocephalosis have been studied through the preclinical testing phase (134). Vaccines against hookworms, onchocerciasis, schistosomiasis, and other geohelminths are in various stages of development (135). Once deployed, these anthelmintic vaccines could be used with anthelmintic drugs in "vaccine-linked chemotherapy" programs to prevent reinfection after MDA (136). In veterinary medicine, a vaccine (TSOL 18) that provides long-lasting control of porcine cysticercosis has been tested in pigs. A control scenario involving vaccination combined with oxfendazole treatment administered at four-month intervals after vaccination proved more effective than the control scenario without vaccination (no pigs slaughtered at 12 months had viable *Taenia solium* cysticerci) (137).

Conclusion

The growing resistance of helminths to currently available drugs underscore the urgent need to identify and validate novel therapeutic options. Medicinal plants are a promising source of anthelmintic molecules, but the transition from traditional use to evidence-based therapeutics requires more than demonstrating in vitro activity. Future research should prioritize the isolation and structural characterization of bioactive compounds, followed by standardized toxicological assessments and rigorous in vivo and clinical trials to confirm safety and efficacy.

The development of plant-derived anthelmintics should rely on an interdisciplinary approach that bridges pharmacology, ethnobotany, microbiology, public health, and regulatory sciences, extending beyond laboratory research. Strategic collaboration between researchers and traditional healers is crucial to identifying relevant species and safeguarding indigenous knowledge through ethical, mutually beneficial frameworks. Ultimately, promising plant-based molecules can only progress toward becoming affordable anthelmintic drugs and being included in treatment protocols by coupling scientific validation with public health planning. This will allow for their potential integration into community-based parasite control programs. This review contributes to this process by synthesizing current knowledge on anthelmintic drug mechanisms, documenting resistance trends, and highlighting the phytochemical and therapeutic potential of medicinal plants.

Conflict of interest

The authors declared no conflict of interest.

Acknowledgments

We would like to express our gratitude to the “Ecole Supérieure des Techniques Biologiques et Alimentaires” (ESTBA) of the University of Lomé for providing us with a scientific framework for our studies.

References

1. Castro GA, Helminths: Structure, Classification, Growth, and Development, in Medical Microbiology, S. Baron, Editor. 1996, University of Texas Medical Branch at Galveston: Galveston (Texas).
2. Organisation WHS-thijAfhwwin-rf-sds-t-h-i.
3. Fahs HZ, et al., A new class of natural anthelmintics targeting lipid metabolism. *Nat Commun*, 2025. 16(1): p. 305.
4. Morales-Montor J, V.H. Del Río-Araiza, and R. Hernández-Bello, Parasitic helminths and zoonoses: From basic to applied research. 2022: BoD–Books on Demand.
5. Geary TG, et al., Unresolved issues in anthelmintic pharmacology for helminthiasis of humans. *International Journal for Parasitology*, 2010. 40(1): p. 1-13.
6. Zhang Q, et al., Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: a case–control study. 2018. 97(42).
7. Liu M, S.K. Panda, and W. Luyten, Plant-based natural products for the discovery and development of novel anthelmintics against nematodes. *Biomolecules*, 2020. 10(3): p. 426.
8. Riaz M, et al., Prevalence, risk factors, challenges, and the currently available diagnostic tools for the determination of helminths infections in human. 2020. 18: p. 2058739220959915.
9. Tchuem Tchuenté LA, Control of soil-transmitted helminths in sub-Saharan Africa: Diagnosis, drug efficacy concerns and challenges. *Acta Tropica*, 2011. 120: p. S4-S11.
10. Hotez PJ, et al., Control of neglected tropical diseases. *N Engl J Med*, 2007. 357(10): p. 1018-27.
11. Adegnika AA, et al., Epidemiology of parasitic co-infections during pregnancy in Lambaréné, Gabon. 2010. 15(10): p. 1204-1209.
12. Hotez PJaJpntdK, Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. 2009. 3(8): p. e412.
13. World Health Organization %J Brazzaville GWHO, Togo: first country in sub-Saharan Africa to eliminate lymphatic filariasis. 2017.
14. Holali Ameyapoh A, Katawa G, Ritter M, Tchopba CN, Tchadie PE, Arndts K, et al. Hookworm Infections and Sociodemographic Factors Associated With Female Reproductive Tract Infections in Rural Areas of the Central Region of Togo. *Front Microbiol*. 2021;12:738894.
15. Manke MB, S.C. Dhawale, and P.G. Jamkhande, Helminthiasis and medicinal plants: a review. *Asian Pacific Journal of Tropical Disease*, 2015. 5(3): p. 175-180.
16. Keiser JaJU, The drugs we have and the drugs we need against major helminth infections. *Advances in parasitology*, 2010. 73: p. 197-230.
17. Fissiha WaMZaK, Anthelmintic Resistance and Its Mechanism: A Review. *Infection and Drug Resistance*, 2021. 14(null): p. 5403-5410.
18. Mullner A, et al., Chemistry and pharmacology of neglected helminthic diseases. 2011. 18(5): p. 767-789.
19. Weng HB, H.X. Chen, and M.W. Wang, Innovation in neglected tropical disease drug discovery and development. *Infect Dis Poverty*, 2018. 7(1): p. 67.
20. Thomford NE, et al., Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition. 2015. 8(3): p. 637-663.
21. Nixon SA, et al., Where are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics. 2020. 14: p. 8-16.
22. Jayawardene KD, E.A. Palombo, and P.R.J.B. Boag, Natural products are a promising source for anthelmintic drug discovery. 2021. 11(10): p. 1457.
23. Cox FE, History of human parasitology. *Clin Microbiol Rev*, 2002. 15(4): p. 595-612.
24. Alum A, J.R. Rubino, and M.K. Ijaz, The global war against intestinal parasites—should we use a holistic approach? *International Journal of Infectious Diseases*, 2010. 14(9): p. e732-e738.
25. Ottesen EAJAip, Lymphatic filariasis: treatment, control and elimination. 2006. 61: p. 395-441.
26. Hoespli RJEP, The knowledge of parasites and parasitic infections from ancient times to the 17th century. 1956. 5(4): p. 398-419.
27. Hotez PJ, Brooker S, Bethony JM, Bottazzi ME, Loukas A, Xiao SJNEJoM. Hookworm infection. 2004;351(8):799-807.
28. Idris OA, O.A. Wintola, and A.J. Afolayan, Helminthiasis; prevalence, transmission, host-parasite interactions, resistance to common synthetic drugs and treatment. *J Heliyon*, 2019. 5(1).
29. Brooker S, A.C. Clements, and D.A. Bundy, Global epidemiology, ecology and control of soil-transmitted helminth infections. *Adv Parasitol*, 2006. 62: p. 221-61.
30. Brooker S, Kabatereine NB, Smith JL, Mupfasoni D, Mwanje MT, Ndayishimiye O, et al. An updated atlas of human helminth infections: the example of East Africa. *International journal of health geographics*. 2009;8(1):42.
31. Katawa G, et al., Hyperreactive onchocerciasis is characterized by a combination of Th17-Th2 immune responses and reduced regulatory T cells. 2015. 9(1): p. e3414.
32. Simfele HC, KATAWA G, Arndts K, Nguépou Tchopba C, AMESSOUDI OM, TCHADIE PE, et al. Is a mass drug administration deworming programme for school-aged children enough to reduce the prevalence of soil-transmitted helminths and *Schistosoma mansoni* in adults: A cross-sectional study from Togo. *Frontiers in Tropical Diseases*.5:1283532.
33. Gazzinelli A, Correa-Oliveira R, Yang G-J, Boatman BA, Kloos HJPntd. A research agenda for helminth diseases of

- humans: social ecology, environmental determinants, and health systems. 2012;6(4):e1603.
34. WHO SoguoiopecantdiJWER, 2020. 95(39): p. 469-474.
 35. World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. Geneva; 2021.
 36. Molyneux D, Neglected tropical diseases. *Community Eye Health*, 2013. 26(82): p. 21-4.
 37. Saratsis A, Sotiraki S, Braae UC, Devleesschauwer B, Dermauw V, Eichenberger RM, et al. Epidemiology of *Taenia saginata* taeniosis/cysticercosis: a systematic review of the distribution in the Middle East and North Africa. *Parasites & vectors*. 2019;12(1):113.
 38. Dermauw V, Dorny P, Braae UC, Devleesschauwer B, Robertson LJ, Saratsis A, et al. Epidemiology of *Taenia saginata* taeniosis/cysticercosis: a systematic review of the distribution in southern and eastern Africa. *Parasites & vectors*. 2018;11(1):578.
 39. Zulu G, Stelzle D, Mwape KE, Welte TM, Strømme H, Mubanga C, et al. The epidemiology of human *Taenia solium* infections: A systematic review of the distribution in Eastern and Southern Africa. *PLoS Neglected Tropical Diseases*. 2023;17(3):e0011042.
 40. Hendrickx E, Thomas LF, Dorny P, Bobić B, Braae UC, Devleesschauwer B, et al. Epidemiology of *Taenia saginata* taeniosis/cysticercosis: a systematic review of the distribution in West and Central Africa. *Parasites & vectors*. 2019;12(1):324.
 41. Haby MM, Sosa Leon LA, Luciañez A, Nicholls RS, Reveiz L, Donadeu M. Systematic review of the effectiveness of selected drugs for preventive chemotherapy for *Taenia solium* taeniasis. *PLoS Neglected Tropical Diseases*. 2020;14(1):e0007873.
 42. Wardle MT, et al., Mass chemotherapy with niclosamide for the control of *Taenia solium*: population-based safety profile and treatment effectiveness. *The Lancet Regional Health—Americas*, 2024. 38.
 43. Abongwa M, Martin RJ, Robertson AP. A brief review on the mode of action of antinematodal drugs. *Acta veterinaria*. 2017;67(2):137.
 44. Jacob J, Siraj MA, Steel A, Tan G, Jarvi S. Evaluation of the mechanism of action of albendazole on adult rat lungworm (*Angiostrongylus cantonensis*). *Experimental parasitology*. 2022;242:108355.
 45. Holden-Dye LaRJW, Avermectin and avermectin derivatives are antagonists at the 4-aminobutyric acid (GABA) receptor on the somatic muscle cells of *Ascaris*; is this the site of anthelmintic action? *Parasitology*, 1990. 101 Pt 2: p. 265-71.
 46. Paul-Odeniran KF, et al., Structural Mechanisms Driving the Selective Efficacy of Oxamniquine against *Schistosoma mansoni* and *Schistosoma japonicum*. 2025: p. 1-17.
 47. Rugel AR, Guzman MA, Taylor AB, Chevalier FD, Tarpley RS, McHardy SF, et al. Why does oxamniquine kill *Schistosoma mansoni* and not *S. haematobium* and *S. japonicum*? *International Journal for Parasitology: Drugs and Drug Resistance*. 2020;13:8-15.
 48. Song Y, Study on the Oxamniquine. *J Academic Journal of Medicine Health Sciences*, 2020. 1(1): p. 60-68.
 49. da Silva VBR, et al., Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine. *Bioorganic & Medicinal Chemistry*, 2017. 25(13): p. 3259-3277.
 50. Doenhoff MJ, D. Cioli, and J. Utzinger, Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. *Curr. Opin. Infect. Dis.*, 2008. 21: p. 659-667.
 51. Pearson RDaRLG, Praziquantel: a major advance in anthelmintic therapy. *Ann Intern Med*, 1983. 99(2): p. 195-8.
 52. Vale N, et al., Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance. *Antimicrob Agents Chemother*. 2017. 61(5).
 53. Kapinder ND, and A.K. Verma, Drug Resistance in Helminth Parasites: Role of Plant-Based Natural Therapeutics, in *Natural Product Based Drug Discovery Against Human Parasites: Opportunities and Challenges*, A. Singh, et al., Editors. 2023, Springer Nature Singapore: Singapore. p. 553-579.
 54. Jayawardene K, Palombo E, Boag P. Natural products are a promising source for anthelmintic drug discovery. *Biomolecules*, 11 (10), 1457. 2021.
 55. Kaplan RMaANV, An inconvenient truth: global worming and anthelmintic resistance. *Vet Parasitol*, 2012. 186(1-2): p. 70-8.
 56. Chevalier FD, et al., Oxamniquine resistance alleles are widespread in Old World *Schistosoma mansoni* and predate drug deployment. 2019. 15(10): p. e1007881.
 57. Geary TG, Chibale K, Abegaz B, Andrae-Marobela K, Ubalijoro E. A new approach for anthelmintic discovery for humans. *Trends in parasitology*. 2012;28(5):176-81.
 58. Jato J, Orman E, Duah Boakye Y, Oppong Bekoe E, Oppong Bekoe S, Asare-Nkansah S, et al. Anthelmintic agents from African medicinal plants: review and prospects. *Evidence-Based Complementary and Alternative Medicine*. 2022;2022(1):8023866.
 59. Gurib-Fakim A, Medicinal plants: Traditions of yesterday and drugs of tomorrow. *Molecular Aspects of Medicine*, 2006. 27(1): p. 1-93.
 60. Patwardhan BJWHO, Traditional medicine: A novel approach for available, accessible and affordable health care. 2005. 13.
 61. Izah SC, et al., Historical Perspectives and Overview of the Value of Herbal Medicine, in *Herbal Medicine Phytochemistry: Applications and Trends*, S.C. Izah, M.C. Ogwu, and M. Akram, Editors. 2024, Springer International Publishing: Cham. p. 3-35.
 62. Tagboto SaST, Antiparasitic properties of medicinal plants and other naturally occurring products, in *Advances in Parasitology*. 2001, Academic Press. p. 199-295.
 63. Karou SD, et al., Ethnobotanical study of medicinal plants used in the management of diabetes mellitus and hypertension in the Central Region of Togo. *Pharm. Biol.*, 2011. 49: p. 1286-1297.

64. Tchacondo T, et al., Herbal remedies and their adverse effects in Tem tribe traditional medicine in Togo. *Afr. J. Tradit. Complement. Altern. Med.*, 2011. 8: p. 45-60.
65. Mali RGaAAM, A review on anthelmintic plants. *Natural Product Radiance*, 2008. 7(5): p. 466-475.
66. Cock I, M. Selesho, and S.J.J.o.e. Van Vuuren, A review of the traditional use of southern African medicinal plants for the treatment of selected parasite infections affecting humans. 2018. 220: p. 250-264.
67. Bajin ba Ndob I, et al., Ethnobotanical survey of medicinal plants used as anthelmintic remedies in Gabon. *Journal of Ethnopharmacology*, 2016. 191: p. 360-371.
68. Haman I, Ngwasiri NN, Ahmadou A, Njintang NY, Ndjonka D. Ethnopharmacology and anthelmintic screening of some plants used in traditional medicine in the Far-North of Cameroon. *Investigational Medicinal Chemistry and Pharmacology*. 2024;7(2).
69. Muthee J, Gakuya D, Mbaria J, Kareru P, Mulei CM, Njonge F. Ethnobotanical study of anthelmintic and other medicinal plants traditionally used in Loitokitok district of Kenya. *Journal of ethnopharmacology*. 2011;135(1):15-21.
70. Mwangi VI, Mumo RM, Nyachio A, Onkoba N. Herbal medicine in the treatment of poverty associated parasitic diseases: A case of sub-Saharan Africa. *Journal of herbal medicine*. 2017;10:1-7.
71. Erhirhie EOaGEJAJoPRM, *Xylopi* aethiopia: A review of its ethnomedicinal, chemical and pharmacological properties. 2014. 4(6): p. 22-37.
72. Katawa G, Ataba E, Ritter M, Amessoudji OM, Awesso ER, Tchadié PE, et al. Anti-Th17 and anti-Th2 responses effects of hydro-ethanolic extracts of *Aframomum melegueta*, *Khaya senegalensis* and *Xylopi* aethiopia in hyperreactive onchocerciasis individuals' peripheral blood mononuclear cells. *PLoS Neglected Tropical Diseases*. 2022;16(4):e0010341.
73. Waterman C, Smith RA, Pontiggia L, DerMarderosian A. Anthelmintic screening of Sub-Saharan African plants used in traditional medicine. *Journal of ethnopharmacology*. 2010;127(3):755-9.
74. Williams AR, Soelberg J, Jäger AK. Anthelmintic properties of traditional African and Caribbean medicinal plants: identification of extracts with potent activity against *Ascaris suum* in vitro. *Parasite*. 2016;23:24.
75. Ataba E, Katawa G, Ritter M, Ameyapoh AH, Anani K, Amessoudji OM, et al. Ethnobotanical survey, anthelmintic effects and cytotoxicity of plants used for treatment of helminthiasis in the Central and Kara regions of Togo. *BMC complementary medicine and therapies*. 2020;20(1):212.
76. Douti FV, Katawa G, Arndts K, Bara FD, Awesso ER, Karou SD, et al. Potential of *Aframomum melegueta* and *Xylopi* aethiopia Against *Taenia* spp.: Plant-Based Remedies as Novel Anthelmintics. *Pharmaceuticals*. 2025;18(5):749.
77. Mhlongo LC, Mseleku C, Tenza T, Fomum SW, McGaw LJ, Hassen A, et al. A review of ethnomedicinal plants as potential anthelmintic agents to alternatively control gastrointestinal nematodes of ruminants in South Africa. *Journal of Parasitology Research*. 2024;2024(1):7955692.
78. Manjusa A, Pradeep K. Herbal anthelmintic agents: a narrative review. *Journal of Traditional Chinese Medicine*. 2022;42(4):641.
79. Ali R, Rooman M, Mussarat S, Norin S, Ali S, Adnan M, et al. A systematic review on comparative analysis, toxicology, and pharmacology of medicinal plants against *Haemonchus contortus*. *Frontiers in Pharmacology*. 2021;12:644027.
80. Esteban-Ballesteros M, Sanchis J, Gutiérrez-Corbo C, Balaña-Fouce R, Rojo-Vázquez FA, González-Lanza C, et al. In vitro anthelmintic activity and safety of different plant species against the ovine gastrointestinal nematode *Teladorsagia circumcincta*. *Research in Veterinary Science*. 2019;123:153-8.
81. Katawa G, Bara FD, Daria F, Tchadie PE, Gnodja T, Arndts K, et al. *Xylopi* aethiopia Fruit Macerate Inhibits Carrageenan-induced Pleurisy in Rats. *Pharmacognosy Research*. 2025;17(3).
82. Awesso ER, Arndts K, Katawa G, Douti FV, Bara FD, Karou SD, et al. Medical Plants *Aframomum melegueta* and *Xylopi* aethiopia Show Low Toxicity in vitro and in vivo Highlighting their Potential for Therapeutic Applications. 2025.
83. Hu Y, Ellis BL, Yiu YY, Miller MM, Urban JF, Shi LZ, et al. An extensive comparison of the effect of anthelmintic classes on diverse nematodes. *PloS one*. 2013;8(7):e70702.
84. Nixon SA, Welz C, Woods DJ, Costa-Junior L, Zamanian M, Martin RJ. Where are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics. *International Journal for Parasitology: Drugs and Drug Resistance*. 2020;14:8-16.
85. Pan S-Y, Zhou S-F, Gao S-H, Yu Z-L, Zhang S-F, Tang M-K, et al. New perspectives on how to discover drugs from herbal medicines: CAM' S outstanding contribution to modern therapeutics. *Evidence-Based Complementary and Alternative Medicine*. 2013;2013(1):627375.
86. Ishnava KB, Konar PS. In vitro anthelmintic activity and phytochemical characterization of *Corallocarpus epigaeus* (Rottler) Hook. f. tuber from ethyl acetate extracts. *Bulletin of the National Research Centre*. 2020;44(1):33.
87. Ferreira LE, Benincasa BI, Fachin AL, Franca SC, Contini SS, Chagas AC, et al. *Thymus vulgaris* L. essential oil and its main component thymol: Anthelmintic effects against *Haemonchus contortus* from sheep. *Veterinary parasitology*. 2016;228:70-6.
88. Mondal H, Hossain H, Awang K, Saha S, Mamun-Ur-Rashid S, Islam MK, et al. Anthelmintic Activity of Ellagic Acid, a Major Constituent of *Alternanthera sessilis* Against *Haemonchus contortus*. *Pakistan Veterinary Journal*. 2015;35(1).
89. Escareño-Díaz S, Alonso-Díaz M, de Gives PM, Castilho-Gallegos E, Von Son-de Fernex E. Anthelmintic-like activity of polyphenolic compounds and their interactions against the cattle nematode *Cooperia punctata*. *Veterinary parasitology*. 2019;274:108909.
90. Spiegler V, Liebau E, Hensel A. Medicinal plant extracts and plant-derived polyphenols with anthelmintic activity

- against intestinal nematodes. *Natural Product Reports*. 2017;34(6):627-43.
91. Williams AR, Fryganas C, Ramsay A, Mueller-Harvey I, Thamsborg SM. Direct anthelmintic effects of condensed tannins from diverse plant sources against *Ascaris suum*. *PLoS one*. 2014;9(5):e97053.
92. Ndjinka D, Djafsia B, Liebau E. Review on medicinal plants and natural compounds as anti-Onchocerca agents. *Parasitology Research*. 2018;117(9):2697-713.
93. Maestrini M, et al., In Vitro Anthelmintic Activity of Saponins from *Medicago* spp. Against Sheep Gastrointestinal Nematodes. *Molecules*, 2020. 25(2).
94. Wangchuk P, Pearson MS, Giacomini PR, Becker L, Sotillo J, Pickering D, et al. Compounds derived from the Bhutanese daisy, *Ajania nubigena*, demonstrate dual anthelmintic activity against *Schistosoma mansoni* and *Trichuris muris*. *PLoS Neglected Tropical Diseases*. 2016;10(8):e0004908.
95. Goel V, Sharma S, Chakraborty NK, Singla LD, Choudhury D. Targeting the nervous system of the parasitic worm, *Haemonchus contortus* with quercetin. *Heliyon*. 2023;9(2).
96. Poolperm S, Jiraungkoorskul W. An update review on the anthelmintic activity of bitter melon, *Momordica charantia*. *Pharmacognosy reviews*. 2017;11(21):31.
97. Preston S, Korhonen PK, Mouchiroud L, Cornaglia M, McGee SL, Young ND, et al. Deguelin exerts potent nematocidal activity via the mitochondrial respiratory chain. *The FASEB Journal*. 2017;31(10):4515-32.
98. Rinaldi G, Loukas A, Brindley PJ, Irelan JT, Smout MJ. Viability of developmental stages of *Schistosoma mansoni* quantified with xCELLigence worm real-time motility assay (xWORM). *International Journal for Parasitology: Drugs and Drug Resistance*. 2015;5(3):141-8.
99. Strober W, Trypan blue exclusion test of cell viability. *Current protocols in immunology*, 2001. 21(1): p. A. 3B. 1-A. 3B. 2.
100. Kamiloglu S, Sari G, Ozdal T, Capanoglu E. Guidelines for cell viability assays. *Food frontiers*. 2020;1(3):332-49.
101. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. *Nature protocols*. 2006;1(3):1458-61.
102. Baskić D, Popović S, Ristić P, Arsenijević NN. Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide. *Cell biology international*. 2006;30(11):924-32.
103. Castillo-Mitre G, Olmedo-Juárez A, Rojo-Rubio R, González-Cortázar M, Mendoza-de Gives P, Hernández-Beteta E, et al. Caffeoyle and coumaroyl derivatives from *Acacia cochliacantha* exhibit ovicidal activity against *Haemonchus contortus*. 2017;204:125-31.
104. Ataba E, al. e. Ethnobotanical survey, anthelmintic effects and cytotoxicity of plants used for treatment of helminthiasis in the Central and Kara regions of Togo. *BMC Complement Med Ther*. 2020a;20:212.
105. Ataba E, al. e. Toxicity, chemical composition, anti-inflammatory and antioxidant activities of plants used for the treatment of helminth infections in the Kara and Central region of Togo. *J Appl Biosci*. 2020b;156:16114-31.
106. Osuntokun OT. *Aframomum melegueta* (grains of paradise). *Annals of Microbiology and Infectious Diseases*. 2020;3(1):1-6.
107. Wangchuk P, Pearson MS, Giacomini PR, Becker L, Sotillo J, Pickering D, et al. Compounds derived from the Bhutanese daisy, *Ajania nubigena*, demonstrate dual anthelmintic activity against *Schistosoma mansoni* and *Trichuris muris*. 2016;10(8):e0004908.
108. Tagoe M, Boakye YD, Agana TA, Boamah VE, Agyare CJJopr. In vitro anthelmintic activity of ethanol stem bark extract of *Albizia ferruginea* (Guill. & Perr.) Benth. 2021;2021(1):6690869.
109. Payne S, Flematti G, Reeder A, Kotze A, Durmic Z, Vercoe P. Procyanidin A2 in the Australian plant *Alectryon oleifolius* has anthelmintic activity against equine cyathostomins in vitro. *Veterinary parasitology*. 2018;249:63-9.
110. Abu Almaaty AH, Rashed HAE-h, Soliman MFM, Fayad E, Althobaiti F, El-Shenawy NS. Parasitological and Biochemical Efficacy of the Active Ingredients of *Allium sativum* and *Curcuma longa* in *Schistosoma mansoni* Infected Mice. 2021;26(15):4542.
111. Doligalska M, Józwicka K, Donskow-Łysoniewska K, Kalinowska M. The antiparasitic activity of avenacosides against intestinal nematodes. *Veterinary parasitology*. 2017;241:5-13.
112. Mukai D, Matsuda N, Yoshioka Y, Sato M, Yamasaki T. Potential anthelmintics: polyphenols from the tea plant *Camellia sinensis* L. are lethally toxic to *Caenorhabditis elegans*. *Journal of Natural Medicines*. 2008;62:155-9.
113. Alhaiqi NS, Afifi SM, Mahyoub JA, Abdel-Gaber RA, Delic D, Dkhil MA. Anthelmintic activity of *Carica papaya* leaf extracts: Insights from in vitro and in silico investigations. *Combinatorial chemistry high throughput screening*. 2025;28(8):1310-9.
114. Muniyiri JM. Anti-Schistosomal Properties of the Wormseed Plant, *Chenopodium Ambrosioides* (Family: Chenopodiaceae): COHES, JKUAT; 2016.
115. Belga FN, Waindok P, Raulf M-K, Jato J, Orman E, Rehbein S, et al. Phytochemical analysis and anthelmintic activity of *Combretum mucronatum* leaf extract against infective larvae of soil-transmitted helminths including ruminant gastrointestinal nematodes. *Parasites & Vectors*. 2024;17(1):99.
116. Grzybek M, Kukula-Koch W, Strachecka A, Jaworska A, Phiri AM, Paleolog J, et al. Evaluation of anthelmintic activity and composition of pumpkin (*Cucurbita pepo* L.) seed extracts—in vitro and in vivo studies. *Int J Mol Sci*. 2016;17:1456.
117. Shai LJ, Bizimenyera ES, Bagla V, McGaw LJ, Eloff JN. *Curtisia dentata* (Cornaceae) leaf extracts and isolated compounds inhibit motility of parasitic and free-living nematodes. *The Onderstepoort journal of veterinary research*. 2009;76(2):249-56.
118. Aderibigbe SA, Idowu SOJJoP, Bioresources. Anthelmintic activity of *Ocimum gratissimum* and

- Cymbopogon citratus leaf extracts against Haemonchus placei adult worm. 2020;17(1):8-12.
119. Preston S, Korhonen PK, Mouchiroud L, Cornaglia M, McGee SL, Young ND, et al. Deguelin exerts potent nematocidal activity via the mitochondrial respiratory chain. 2017;31(10):4515-32.
120. Samoylenko V, Dunbar DC, Gafur MA, Khan SI, Ross SA, Mossa JS, et al. Antiparasitic, nematocidal and antifouling constituents from Juniperus berries. Phytotherapy research : PTR. 2008;22(12):1570-6.
121. Grando T, De Sá M, Baldissera M, Oliveira C, De Souza M, Raffin R, et al. In vitro activity of essential oils of free and nanostructured Melaleuca alternifolia and of terpinen-4-ol on eggs and larvae of Haemonchus contortus. 2016;90(3):377-82.
122. Poolperm S, Jiraungkoorskul W. An Update Review on the Anthelmintic Activity of Bitter Gourd, Momordica charantia. Pharmacognosy reviews. 2017;11(21):31-4.
123. Soldera-Silva A, Seyfried M, Campestrini LH, Zawadzki-Baggio SF, Minho AP, Molento MB, et al. Assessment of anthelmintic activity and bio-guided chemical analysis of Persea americana seed extracts. Veterinary parasitology. 2018;251:34-43.
124. Paul A, Adnan M, Majumder M, Kar N, Meem M, Rahman MS, et al. Anthelmintic activity of Piper sylvaticum Roxb. (family: Piperaceae): In vitro and in silico studies. Clinical Phytoscience. 2018;4(1):17.
125. Palchykov V, Zazharskyi V, Brygadyrenko V, Davydenko P, Kulishenko O, Borovik I, et al. Bactericidal, protistocidal, nematocidal properties and chemical composition of ethanol extract of Punica granatum peel. Biosystems Diversity. 2019;27(3):300-6.
126. Soren AD, Lalthanpuii PB, Lalchandama KJB. GC-MS, antioxidant study and effect of Sesbania sesban var. bicolor on Raillietina echinobothrida and Syphacia obvelata. 2024;79(6):1851-9.
127. Jasso Díaz G, Hernández GT, Zamilpa A, Becerril Pérez CM, Ramírez Bribiesca JE, Hernández Mendo O, et al. In vitro assessment of Argemone mexicana, Taraxacum officinale, Ruta chalepensis and Tagetes filifolia against Haemonchus contortus nematode eggs and infective (L3) larvae. Microbial Pathogenesis. 2017;109:162-8.
128. Van Puyvelde L, Liu M, Veryser C, De Borggraeve WM, Mungarulire J, Mukazayire MJ, et al. Active principles of Tetradenia riparia. IV. Anthelmintic activity of 8(14),15-sandaracopimaradiene-7 α ,18-diol. Journal of Ethnopharmacology. 2018;216:229-32.
129. Ferreira LE, Benincasa BI, Fachin AL, Franca SC, Contini SS, Chagas AC, et al. Thymus vulgaris L. essential oil and its main component thymol: Anthelmintic effects against Haemonchus contortus from sheep. 2016;228:70-6.
130. Liu M, Panda SK, Luyten W. Plant-Based Natural Products for the Discovery and Development of Novel Anthelmintics against Nematodes. Biomolecules. 2020;10:426.
131. Raza A, Muhammad F, Bashir S, Aslam B, Anwar MI, Naseer MU. In-vitro and in-vivo anthelmintic potential of different medicinal plants against Ascaridia galli infection in poultry birds. World's Poultry Science Journal. 2016;72(1):115-24.
132. Quartey A, Oppong A, Ayensu I, Apenteng J, Mintah D, Ikeani C. Synergistic in-vitro anthelmintic potentials of Vernonia amygdalina Delile stem and Carica papaya Lin. seeds. Planta Medica International Open. 2017;4(S 01):Tu-PO-103.
133. Wang J, Song H, Wu X, Zhang S, Gao X, Li F, et al. Steroidal Saponins from Vernonia amygdalina Del. and Their Biological Activity. Molecules (Basel, Switzerland) [Internet]. 2018; 23(3).
134. Apenteng JA, Ogundeyi M, Oppong EE, Osei-Asare C, Brookman-Amisah MG. In vitro Anti-infective and Antioxidant activity of Xylopi aethiopia [Dun.] A. Rich: A comparison of the fruits and leaves extracts. Journal of Medicinal Plants Studies. 2016;4(5):24-9.
135. Osafo N, Obiri DD, Antwi AO, Yeboah OK. The acute anti-inflammatory action of xylopic acid isolated from Xylopi aethiopia. 2018;29(6):659-69.
136. Bergquist RaSJAipL. Control of Important Helminthic Infections: VaccineDevelopment as Part of the Solution. 2010. 73: p. 297-326.
137. Lightowers MW. Control of Taenia solium taeniasis/cysticercosis: past practices and new possibilities. Parasitology.2013;140(13):1566-77.